ARL17A (ARF-like GTPase 17A) is a small GTPase involved in intracellular protein transport and vesicle-mediated trafficking 1. The gene encodes a GTP-binding protein localized to the nucleoplasm, cytoplasm, and plasma membrane, functioning in cellular transport processes [GO annotations provided]. ARL17A exhibits pleiotropic effects across multiple neurological and neurodegenerative conditions. It was identified as a pleiotropic locus influencing over 50 hippocampal and subfield volume-neuropsychiatric trait pairs, with particular relevance to Parkinson's disease risk 1. The gene was also implicated in essential tremor aetiology through linkage analysis of familial cases and associated with tremor network structure through transcriptomic associations 23. Additionally, ARL17A was identified as one of ten genes with pleiotropic effects on both primary open-angle glaucoma and Alzheimer's disease, with evidence that retinal and brain cortex-specific expression influences glaucoma risk 4. ARL17A is notably involved in the recurrent KANSL1-ARL17A fusion gene, which generates oncogenic chimeric RNAs driving lung cancer progression through a circular RNA-miRNA regulatory axis 56. The gene also shows disease associations in progressive supranuclear palsy, where brain expression levels correlate with PSP risk variants and neuropathology 7, and influences TH2 cell function in COVID-19 pathogenesis 8.